SABRINA: Phase 3 study comparing subcutaneous and intravenous rituximab in follicular lymphoma | Dr Andrew Davies at EHA 2015
At the 20th Congress of the European Hematology Association (EHA), Andrew Davies, BSc (Hons), BM (Hons), MRCP, PhD, of the University of Southampton, Southampton, UK, provides an update on the safety ... Author: EMJ Added: 06/29/2015 (Source: Oncology Tube)
Source: Oncology Tube - June 29, 2015 Category: Cancer & Oncology Source Type: podcasts

HELIOS: Phase 3 trial of ibrutinib combined with bendamustine and rituximab in previously treated CLL/SLL | Dr Paula Cramer at EHA 2015
At the 20th Congress of the European Hematology Association (EHA), Paula Cramer, MD, of the University Hospital Cologne, Cologne, Germany, discusses the first results from the phase 3 HELIOS trial, wh... Author: EMJ Added: 06/29/2015 (Source: Oncology Tube)
Source: Oncology Tube - June 29, 2015 Category: Cancer & Oncology Source Type: podcasts

Intravenous Versus Subcutaneous Rituximab
Martin Barrett on Intravenous Versus Subcutaneous Rituximab Author: onclivetv Added: 06/22/2015 (Source: Oncology Tube)
Source: Oncology Tube - June 22, 2015 Category: Cancer & Oncology Source Type: podcasts

EHA 2015: Venetoclax (ABT-199/GDC-0199) combined with rituximab induces deep responses in patients with relapsed/refractory CLL
In a phase 1b, open-label, dose-escalation, multicentre study of patients with relapsed or refractory chronic lymphocytic leukaemia (CLL), the combination of the BCL-2 inhibitor, venetoclax (ABT-199/G... Author: EMJ Added: 06/13/2015 (Source: Oncology Tube)
Source: Oncology Tube - June 13, 2015 Category: Cancer & Oncology Source Type: podcasts

ASCO 2015: New Ibrutinib Combination Regimen Shows Substantial Benefits in Relapsed Chronic Lymphocytic Leukemia
An interim analysis of a large phase III study suggests that the combination of ibrutinib and bendamustine/rituximab (BR) improves outcomes for patients with chronic-lymphocytic leukemia (CLL) that wo... Author: EMJ Added: 06/03/2015 (Source: Oncology Tube)
Source: Oncology Tube - June 3, 2015 Category: Cancer & Oncology Source Type: podcasts

Advice for Coping with a CLL Relapse
A therapist from Ontario, Canada, Mark Silverstein, underwent FCR (fludarabine, cyclophosphamide, rituximab) to treat his chronic lymphocytic leukemia in 2011. Now with signs of a relapse, Mark may be... Author: patientpower Added: 05/13/2015 (Source: Oncology Tube)
Source: Oncology Tube - May 14, 2015 Category: Cancer & Oncology Source Type: podcasts

Phase III Study of Idelalisib /Rituximab for Relapsed Chronic Lymphocytic Leukemia
Dr. Jeff Sharman analysis of a phase 3 study of idelalisib plus rituximab for relapsed chronic lymphocytic leukemia: efficacy analysis in patient subpopulations with Del(17p) and other adverse prognos... Author: feeds Added: 04/15/2015 (Source: Oncology Tube)
Source: Oncology Tube - April 15, 2015 Category: Cancer & Oncology Source Type: podcasts

Lenalidomide Plus Rituximab as Initial Treatment for Mantle Cell Lymphoma: Sustained Remission
A Multi-Center Phase II Study Report (Abstract 625). At ASH 2014, Dr. Jia Ruan discussed her paper on Sustained Remission with the Combination Biologic Doublet of Lenalidomide Plus Rituximab As Initi... Author: feeds Added: 04/15/2015 (Source: Oncology Tube)
Source: Oncology Tube - April 15, 2015 Category: Cancer & Oncology Source Type: podcasts

Bendamustine in With Rituximab for Untreated CLL Patients
An Italian Retrospective Multicentre Study (Abstract 1985). At ASH 2014, Dr. Fortunato Morabito discussed his abstract titled Bendamustine in Combination with Rituximab for Previously Untreated Chron... Author: feeds Added: 04/15/2015 (Source: Oncology Tube)
Source: Oncology Tube - April 15, 2015 Category: Cancer & Oncology Source Type: podcasts

Dr Jia Ruan at ASH 2014: Phase II study of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma (Part 2 of 2)
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jia Ruan (Weill Cornell Medical College, New York, NY) discusses the clinical relevance of a phase II study of the biologic doublet ... Author: EMJ Added: 04/13/2015 (Source: Oncology Tube)
Source: Oncology Tube - April 13, 2015 Category: Cancer & Oncology Source Type: podcasts

Dr Jia Ruan at ASH 2014: Phase II study of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma (Part 1 of 2)
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jia Ruan (Weill Cornell Medical College, New York, NY) discusses a phase II study of the biologic doublet of lenalidomide plus ritux... Author: EMJ Added: 04/13/2015 (Source: Oncology Tube)
Source: Oncology Tube - April 13, 2015 Category: Cancer & Oncology Source Type: podcasts

Dr.Ruan Discusses Lenalidomide Plus Rituximab in MCL
Sustained remissions experienced by patients treated with the combination of lenalidomide and rituximab as initial treatment for mantle cell lymphoma. Jia Ruan, MD, PhD, is an associate professor at ... Author: onclivetv Added: 02/24/2015 (Source: Oncology Tube)
Source: Oncology Tube - February 24, 2015 Category: Cancer & Oncology Source Type: podcasts

Prof Bertrand Coiffier at ASH 2014: Phase III prospective Lyma trial of rituximab maintenance after ASCT in young previously untreated mantle cell lymphoma
At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Bertrand Coiffier (Centre Hospitalier Lyon-Sud, Pierre-Benite, France) discusses the first interim analysis of the phase III prosp... Author: EMJ Added: 01/27/2015 (Source: Oncology Tube)
Source: Oncology Tube - January 27, 2015 Category: Cancer & Oncology Source Type: podcasts

ASFH Rituximab and Orbital Inflammatory Disease
Guest: Eric B. Suhler, MD, MPH Associate Professor of Ophthalmology Oregon Health & Science University Chief of Ophthalmology Portland Veterans Administration Medical Center Portland, OR (Source: As Seen From Here)
Source: As Seen From Here - July 5, 2014 Category: Opthalmology Authors: JYoungMD at gmail.com Source Type: podcasts

ASFH Rituximab and Orbital Inflammatory Disease
Guest: Eric B. Suhler, MD, MPH Associate Professor of Ophthalmology Oregon Health & Science University Chief of Ophthalmology Portland Veterans Administration Medical Center Portland, OR (Source: As Seen From Here)
Source: As Seen From Here - July 5, 2014 Category: Opthalmology Authors: JYoungMD at gmail.com Source Type: podcasts